Business ❯ Pharmaceuticals

Vaccine Development

Moderna Clinical Trials Novavax Market Impact Moderna Inc. Funding AstraZeneca Research Funding Market Reactions Corporate Governance mRNA Technology Collaboration Agreements Research and Development Contracts Public Health Response Market Competition COVID-19 Vaccines COVID-19 Vaccine Clinical Research Pricing Strategies Covid-19 Vaccines Corporate Deals Cancer Vaccine Regulatory Affairs Market Response Seattle-based Manufacturing Investment Decisions Manufacturing Agreements Market Performance Manufacturers Company Acquisitions Valneva Valneva SE Technology Transfer Corporate Communication Pfizer Acquisitions

Pfizer and BioNTech Halt U.S. COVID Vaccine Trial for 50–64-Year-Olds Over Slow Enrollment

Tougher FDA rules are squeezing efforts to test shots in healthy adults 50 to 64.

CEPI Puts Up to $54.3 Million Behind Moderna’s H5 mRNA Bird Flu Vaccine for Phase 3

FDA Suspends Valneva’s Ixchiq Chikungunya Vaccine Over Safety Reports

Moderna’s mRNA-1010 Flu Vaccine Outperforms Standard Shot and Advances Toward Approval

FDA Expands Moderna RSV Vaccine to Adults 18–59 at Risk

FDA Approves Moderna’s mNEXSPIKE for Seniors and High-Risk Adults as CDC Drops Recommendations for Healthy Children and Pregnant Women

HHS Withdraws $766 Million From Moderna’s Bird Flu Vaccine Program

Moderna Withdraws Flu-COVID Vaccine Application After FDA Requests More Data

FDA Grants Limited Approval to Novavax’s COVID-19 Vaccine